Back to Results
First PageMeta Content
Myelodysplastic syndrome / Syndromes / Acute myeloid leukemia / Leukemia / Thrombocytopenia / Neutropenia / Cytarabine / Anemia / Medicine / Oncology / Hematopathology


FDA Accepts DACOGEN(R) (Decitabine) sNDA Submission in Acute Myeloid Leukemia DUBLIN, Calif., Jul 13, 2011 (BUSINESS WIRE) -SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and developmen
Add to Reading List

Open Document

File Size: 16,67 KB

Share Result on Facebook

City

DUBLIN / /

Company

Eisai Inc. / Astex Therapeutics Limited / SuperGen Inc. / /

Country

United Kingdom / /

/

Event

M&A / FDA Phase / /

IndustryTerm

treatment of acute myeloid leukemia / biotechnology / cancer therapies / cancer therapeutics / pharmaceutical / /

MedicalCondition

uncontrolled infection / cancer / petechiae / chronic myelomonocytic leukemia / disease / Acute Myeloid Leukemia DUBLIN / leukopenia / myelodysplastic syndromes / hyperglycemia / refractory anemia / novel cancer / neutropenia / nausea / thrombocytopenia / hepatic dysfunction / fatigue / diarrhea / infection / cough / constipation / infections / acute myeloid leukemia / anemia / /

MedicalTreatment

contraception / cancer therapies / cancer therapeutics / /

Organization

U.S. Food and Drug Administration / /

Person

Michael Ares / Timothy L. Enns / Susanna Chau / /

/

Position

Director aroemer@troutgroup.com / Manager Investor Relations schau@supergen.com / Senior Vice President michael.ares@fleishman.com / Managing Director / physician / Senior Vice President Corporate Communications & Business Dev / /

Product

cytarabine / DACOGEN / FDA Accepts DACOGEN(R) (Decitabine) / /

ProvinceOrState

California / /

Technology

biotechnology / cell signaling / /

URL

http /

SocialTag